Regeneron Pharma (REGN) PT Raised to $388 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
January 8, 2018 7:04 AM ESTTARRYTOWN, N.Y. and PARIS, Jan. 8, 2018 /PRNewswire/ --Â Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology, and the IL-4/IL-13 pathway-blocking antibody dupilumab in Type 2 allergic diseases. Both of these breakthrough therapies have the potential to benefit a number of different patient populations, and this strategic investment will enable the companies to evaluate cemiplimab and dupilumab in broader clinical development programs.
Under the terms of the expansion, the investment in cemiplimab will be increased to... More
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
January 8, 2018 7:02 AM ESTÂ Press Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
Paris and Tarrytown, N.Y.... More
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
January 8, 2018 7:01 AM ESTÂ Press Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development... More
Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank
January 8, 2018 7:00 AM ESTTARRYTOWN, N.Y., Jan. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), along with new collaborators AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer Inc., today announced the formation of a major 'pre-competitive' consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource. The newly announced collaborators will each commit $10 million to enable a dramatic acceleration of sequencing timelines, and additional companies are considering joining the consortium. Regeneron will conduct the sequencing effort. The sequencing data will be paired with... More
